The epidemiology of mycosis fungoides in New Zealand

Chang, Fen-Lan Cherry; Coomarasamy, Christin; Jarrett, Paul

doi:10.1111/ajd.13616

Cited by 2 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MF and SS commonly affect the male gender in the fifth decade of life. Different studies have estimated that CTCL incidence has been tripled over the last three decades, with a number of new cases raised from 0.19 case/100,000 people/year to 0.46 among Dutch population [ 1 , 2 , 3 , 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

TOX Expression in Mycosis Fungoides and Sezary Syndrome

et al. 2022

View full text Add to dashboard Cite

Mycosis fungoides (MF) and Sezary syndrome (SS) are the two most common type of cutaneous T-cell lymphoma (CTCL). Currently, no markers can be clearly related to prognosis or to differential diagnosis between early stages and inflammatory benign diseases (IBD). The thymocyte selection-associated high mobility group box factor (TOX), has been proposed as a possible marker in differential diagnosis between early CTCL stages and IBD. Recently TOX has been related to prognosis. We aimed to investigate whether TOX may be a diagnostic or prognostic marker. MF and SS biopsies between 2010 and 2020 were retrieved. New tissues slides were stained with an anti-TOX antibody, (Clone NAN448B). On each slide, 5 fields were examined at high magnification (400×), to evaluate the percentage of marker-positivity in a quantitative way. Thirty-six patients (12 females and 24 males) and 48 biopsies were collected. Nine patients had multiple biopsies. TOX expression in MF/SS cases showed an increase from early to advanced phases. TOX was not regarded as a prognostic marker due to the absence of significant changes by comparing early MF cases with reactive conditions. TOX statistical significance increased in patients alive with disease and in those dead of disease (p = 0.013 and = 0.0005, respectively) as compared with patients in complete remission. Our results show that TOX should be regarded more as a prognostic than a diagnostic marker.

show abstract

Section: Introductionmentioning

confidence: 99%

TOX Expression in Mycosis Fungoides and Sezary Syndrome

et al. 2022

View full text Add to dashboard Cite

show abstract

“…To date, there have been small immunohistochemical studies examining PD-L1 expression in EMPD, summarised including our case in Table 1. [1][2][3][4][5][6][7][8][9][10] Although several studies reported low PD-L1 expression at EMPD, only a limited number of studies separately examined in situ and invasive cases. In a study by Duverger et al, PD-L1 was expressed in invasive EMPD cases (4 of 7; 57.1%).…”

Section: Research Lettermentioning

confidence: 99%

“…1,[6][7][8] Radiation therapy has been employed for decades to treat BCC and SCC, either definitively or as an adjuvant to surgical excision, in higher doses than what we report in this case. 9,10 Only one case series has reported on the successful use of radiation therapy in treating DSAP, using low-energy Grenz rays. 5 Thus, wide-field VMAT with its capacity to be highly conformal and able to treat large, curved skin surfaces such as the legs and back with a homogenous dose may be a suitable option in complex DSAP with concomitant field cancerisation.We thus report a case of successful treatment of extensive DSAP and concurrent non-melanoma skin cancer in an elderly patient with low-dose VMAT.…”

mentioning

confidence: 99%

Expression of programmed cell death ligand 1 (PD‐L1) at in situ and invasive extramammary Paget’s disease and literature review

et al. 2021

View full text Add to dashboard Cite

DSAP lesions are premalignant with conversion rates of 7.5 to 10%, most commonly to SCC; thus, there is a need to ensure that DSAP is treated effectively early in the disease course. 3,4 DSAP can be difficult to manage; however, treatment may include topical imiquimod and fluorouracil, vitamin D 3 analogues, topical and oral retinoids, topical cholesterol/lovastatin, cryotherapy, excision, curettage, laser ablation, photodynamic therapy and radiation therapy. 1,3,[5][6][7][8] The efficacy and long-term durability of these treatments vary, and current data are primarily from case reports and case series. 1,[6][7][8] Radiation therapy has been employed for decades to treat BCC and SCC, either definitively or as an adjuvant to surgical excision, in higher doses than what we report in this case. 9,10 Only one case series has reported on the successful use of radiation therapy in treating DSAP, using low-energy Grenz rays. 5 Thus, wide-field VMAT with its capacity to be highly conformal and able to treat large, curved skin surfaces such as the legs and back with a homogenous dose may be a suitable option in complex DSAP with concomitant field cancerisation.We thus report a case of successful treatment of extensive DSAP and concurrent non-melanoma skin cancer in an elderly patient with low-dose VMAT. Given these findings, we suggest that VMAT could be considered a suitable treatment option for patients with complex DSAP who have failed other treatments.

show abstract

The epidemiology of mycosis fungoides in New Zealand

Cited by 2 publications

References 9 publications

TOX Expression in Mycosis Fungoides and Sezary Syndrome

TOX Expression in Mycosis Fungoides and Sezary Syndrome

Expression of programmed cell death ligand 1 (PD‐L1) at in situ and invasive extramammary Paget’s disease and literature review

Contact Info

Product

Resources

About